A Feasibility Study of MRI and PET Imaging to Assess Response to MK-3475 (Pembrolizumab) in Patients With Metastatic Melanoma

Trial Profile

A Feasibility Study of MRI and PET Imaging to Assess Response to MK-3475 (Pembrolizumab) in Patients With Metastatic Melanoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Diagnostic use
  • Acronyms MPAK
  • Most Recent Events

    • 23 Jan 2018 Planned End Date changed from 1 Nov 2017 to 1 Nov 2024.
    • 23 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2022.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top